Please visit answersincme.com/BWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric asthma discusses how to identify children with uncontrolled asthma who could benefit from an add-on biologic. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment with add-on biologic therapy; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate-to-severe asthma; and Outline patient-centered strategies to enhance outcomes for pediatric patients with inadequately controlled moderate-to-severe asthma.

Please visit answersincme.com/DUR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an allergist and immunologist discusses individualized treatment for children with moderate-to-severe asthma. Upon completion of this activity, participants should be better able to: Identify pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from add-on biologic therapy; Describe the clinical profiles of available biologics for the management of inadequately controlled moderate-to-severe asthma in pediatric patients; and Outline strategies to provide individualized, evidence-based treatment for inadequately controlled moderate-to-severe asthma in pediatric patients.

Please visit answersincme.com/GDJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses strategies to reduce low-density lipoprotein cholesterol (LDL-C) in patients with severe familial hypercholesterolemia (FH). Upon completion of this activity, participants should be better able to: Describe the clinical impact of early and intensive treatment for patients with severe FH, including homozygous FH (HoFH); Discuss the clinical profiles of novel strategies to reduce LDL-C in patients with severe FH; and Outline guideline- and expert-recommended novel strategies across patient ages to reduce LDL-C in patients with severe FH.

Please visit answersincme.com/JUK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in immunology discusses the burden of respiratory syncytial virus (RSV) in older adults and the clinical impact of late-stage emerging RSV vaccines. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for vaccines to prevent respiratory syncytial virus (RSV) in older adults; Identify factors contributing to poor RSV outcomes in older adults; and Describe the clinical significance of available data for late-stage investigational RSV vaccines in older adults.

Please visit answersincme.com/QMD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses the management of elevated low-density lipoprotein (LDL) cholesterol in patients with severe familial hypercholesterolemia (FH). Upon completion of this activity, participants should be better able to: Identify patients with FH; Describe the clinical impact of early and intensive treatment for patients with severe FH, including homozygous FH (HoFH); and Discuss the clinical profiles of novel strategies to reduce LDL cholesterol in patients with severe FH.

Please visit answersincme.com/MDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the impact of adjuvant immune checkpoint inhibitors (ICIs) on outcomes in patients with resected early-stage non-small cell lung cancer (NSCLC), and how to optimally integrate them into practice based on recent evidence. Upon completion of this activity, participants should be better able to: Review guideline-recommended adjuvant treatment options for patients with surgically resected early-stage NSCLC; Describe the clinical evidence for novel ICIs being investigated for the adjuvant treatment of surgically resected early-stage NSCLC; and Outline clinical considerations for the use of novel adjuvant ICIs in the management of patients with surgically resected early-stage NSCLC.